Vitamin D and Melanoma: What Do We Tell Our Patients?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Cutaneous malignant melanoma incidence is strongly associated with European depigmented skin type regardless of ambient ultraviolet radiation levels: evidence from Worldwide population-based data.AIMS public health · 2022
   Article
2. Development of novel parameter for monitoring of malignant melanoma progression.Practical laboratory medicine · 2020
   Article
3. Serum Total 25-Hydroxyvitamin D Levels in Patients With Cutaneous Malignant Melanoma: A Case-Control Study in a Low-Risk Southern European Population.Dermatology practical & conceptual · 2020
   Article
4. The interaction between vitamin D receptor polymorphisms and sun exposure around time of diagnosis influences melanoma survival.Pigment cell & melanoma research · 2018
   Article

Corrections and comments

• Comment on
  Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein.2016

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as